11,10 €
4,45 % gestern
L&S, 30. Oktober, 22:52 Uhr
ISIN
JE00BYSS4X48
Symbol
NVCR
Berichte

Novocure Ltd. Aktie News

Neutral
Seeking Alpha
etwa 9 Stunden alt
NovoCure Limited ( NVCR ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Ingrid Goldberg - VP of Investor Relations William Doyle - Executive Chairman Ashley Cordova - CEO & Director Christoph Brackmann - Chief Financial Officer Frank Leonard - President Conference Call Participants Jason Bednar - Piper Sandler & Co., Research Division Kevin Joaquin - Evercore ISI Insti...
Neutral
Business Wire
etwa 18 Stunden alt
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the third quarter that ended September 30, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “Q3 was a solid quarter with steady commercial ...
Positiv
Seeking Alpha
14 Tage alt
Novocure Limited (NVCR) is rated BUY, driven by expanding regulatory approvals, breakthrough clinical results, and a robust late-stage pipeline in cancer therapy. NVCR's Tumor Treating Fields technology offers a differentiated, device-based approach to cancer treatment, with recent milestones in glioblastoma, lung, and pancreatic cancers. Upcoming Q3 results and regulatory updates, including ME...
Neutral
Business Wire
16 Tage alt
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it will present data at two upcoming oncology congresses, the 2025 European Association of Neuro-Oncology (EANO) Meeting, being held October 16-19 in Prague, Czech Republic, and the European Society for Medical Oncology (ESMO) Congress 2025, being held October 17-21 in Berlin, Germany. At the EANO 2025 Meeting, Nov...
Neutral
Business Wire
30 Tage alt
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2025 on October 30, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 30, to discuss the company's financial results for the three- and nine-month periods that ended September 30, 2025. To access the con...
Neutral
Business Wire
etwa ein Monat alt
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced that final results from the Phase 3 METIS trial of Tumor Treating Fields (TTFields) therapy for brain metastases from non-small cell lung cancer (NSCLC) will be presented today at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting taking place September 27 – October 1 in San Francisco and simultaneously p...
Neutral
Business Wire
etwa 2 Monate alt
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors for the treatment of adult patients with unresectable advanced/recurrent non-small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy. “With the Ministry of Heal...
Neutral
Seeking Alpha
etwa 2 Monate alt
NovoCure Limited (NASDAQ:NVCR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 3:20 PM EDT Company Participants Ashley Cordova - CEO & Director Conference Call Participants Kelly McCarthy - Morgan Stanley Presentation Kelly McCarthy Good afternoon, everyone, and we appreciate you joining us for a fireside chat with NovoCure. I'm very happy to be joined by CEO, Ashley...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen